not for human or veterinary use Key Characteristics of Klow BPC 157 10 mg + GHKCu 50 mg + TB500 10 mg + KPV 10 mg Multi-peptide design: Combines four peptides studied in models related to tissue structure, vascular biology, and inflammatory signalingsupporting multi-pathway exploration in one formulation
Originally engineered at Washington State University by the Harding lab and later licensed to M3 Biotechnology, Dihexa retains the angiotensin IV pharmacophore for AT4 receptor binding while incorporating N-hexanoyl and aminohexanoic acid modifications that confer metabolic stability and lipophilic BBB penetration
Unlike approaches that mask symptoms, it addresses the root cause of age-related decline for more complete restoration
Br J Cancer (2019) 120(1):1625
Many clients combine approaches sequentially or strategically (e.g., use GLP-1s for 612 months to reach a metabolic milestone, then taper while layering peptide protocols to support maintenance, sleep, and recovery)